Brii Biosciences Limited
BRIBF · OTC
6/30/2025 | 12/31/2024 | 6/30/2024 | 12/31/2023 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 0.12 | 0.03 | 0.00 | -0.18 |
| FCF Yield | 0.00% | -22.35% | -34.05% | -20.21% |
| EV / EBITDA | 1.76 | 3.27 | -0.14 | -2.55 |
| Quality | ||||
| ROIC | -3.57% | -3.57% | -7.62% | -9.04% |
| Gross Margin | 100.00% | 100.00% | 100.00% | 100.00% |
| Cash Conversion Ratio | – | 0.63 | 0.80 | -15.92 |
| Growth | ||||
| Revenue 3-Year CAGR | -27.41% | -3.38% | 61.16% | 106.79% |
| Free Cash Flow Growth | 100.00% | 33.98% | 5.70% | 32.09% |
| Safety | ||||
| Net Debt / EBITDA | 17.33 | 10.42 | 2.98 | 1.77 |
| Interest Coverage | 0.00 | 0.00 | 0.00 | 0.00 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Conversion Cycle | 0.00 | 0.00 | 0.00 | 96.98 |